Increasing both the number of shares and share price, iTeos Therapeutics has raised more than $201m in an offering that provided an exit to 6 Dimensions Capital.

UC Berkeley's genetic drug developer 4DMT has pulled away from a proposed $100m offering after closing series C funding last month.

Pfizer and Chiesi-backed genetic drug developer 4DMT has pulled away from a proposed $100m offering after closing series C funding last month.

UCL's gene therapy developer has followed a $120m round co-led by Novo three weeks ago by filing to go public on the Nasdaq Global Select Market.

Alibaba's financial services spinoff plans to float concurrently in Shanghai and Hong Kong, with China Life and China Post among the investors in line for exits.

Tencent, Info Edge and SoftBank-banked Policybazaar is aiming for $250m in a round set to precede a 2021 initial public offering expected to value it at $3.5bn.

The gene therapy developer has followed a $120m round co-led by Novo three weeks ago by filing to go public on the Nasdaq Global Select Market.

Novo-backed immuno-oncology drug developer Checkmate Pharmaceuticals has filed to go public a month after its last funding round.

UC Berkeley-linked cell biology technology developer Berkeley Lights floated in a $178m offering and its shares almost tripled in price on their first day of trading.

The Nikon and Varian-backed cell biology technology developer floated in a $178m offering and its shares almost tripled in price on their first day of trading.